Delivering innovative medicines to patients where no others have proven effective or existed. See our community guidelines: https://teapaw.org/t.co/HWH9JQRBR2
Carlsbad, CA
Joined December 2015
- Tweets1.5K
- Following460
- Followers5.1K
- Likes788
Developed with @NatTgAlliance, experts and the high triglycerides community, with support from Ionis, the Hidden in Plain Sight white paper examines the actions required to close the gaps in care for very high triglycerides.
Learn more: bit.ly/4sS5H5f
#IONISInnovation
ALT The image is a promotional graphic with a quote about raising awareness among medical colleagues regarding elevated triglycerides and pancreatitis. It includes a headshot of a person identified as Ann Liebseskind, described as a clinical contributor to a white paper. The background is purple, and the Ionis logo is at the bottom right.
Today we reported Q3 2026 financial results. Read more and tune in live to the webcast today at 9:00 AM ET: bit.ly/4eYyRK5
$IONS
1
590
#ACAAI2026 brings together allergists and immunologists working to advance care for people living with hereditary angioedema (#HAE). We look forward to connecting and sharing insights on our RNA-targeted science. Learn more: ionis.com/science-and-innova…
#IONISinnovation
Save the date for our Q3 2026 earnings webcast. Register now and tune in live on November 9 at 9:00 am ET: bit.ly/4zkAERR $IONS
Today, with our partner @Roche, we announced new positive data from a Phase 3 study for an investigational medicine for the treatment of IgA nephropathy (IgAN). Read more: bit.ly/4z7vyZi
$IONS
The CHMP in the European Union recommended the approval of Ionis’ and Sobi’s treatment for severe hypertriglyceridemia (sHTG). Read more: bit.ly/4B9cRFX
$IONS
Today marks an important step forward for the FUS-ALS community and for our shared goal of advancing a new treatment option for people living with this rare, rapidly progressive form of genetic #ALS.
Read more: bit.ly/3V5Un8O
$IONS
Today w/ partner Otsuka we announced positive topline results from the Ph3 FUSION study evaluating an investigational RNA-targeted medicine for people w/ amyotrophic lateral sclerosis (#ALS) caused by mutations in the fused in sarcoma (FUS) gene: ir.ionis.com/news-releases/n…
$IONS
Academics, don’t miss this opportunity to share your cutting-edge insights in RNA-targeted technology. Submit your abstract now through October 1st for a chance to contribute to the conversation, or register to attend by November 10th: bit.ly/4javGlm
#RNAbench2bedside
Today, with our partner @Novartis , we announced topline results from the Phase 3 Lp(a)HORIZON clinical trial in patients with cardiovascular disease and elevated levels of Lp(a).
Learn more: ir.ionis.com/news-releases/n…
Ionis will host an investor webcast to discuss the U.S. FDA approval of our medicine for Alexander disease (#AxD). Access a link to the webcast: app.webinar.net/Pjnb9l1LZ0D
BREAKING NEWS: We’re proud to share that we have received U.S. FDA approval for ZANVASTRO™ (zilganersen), an important advance for patients and a meaningful milestone in our work to address serious neurological diseases. Read more: ir.ionis.com/news-releases/n… $IONS
Hear from Ionis’ Sam Tsimikas (@Lpa_Doc) about the four emerging trends that are poised to shape future severe hypertriglyceridemia (#sHTG) management: bit.ly/4gF4J6r
#IONISinnovation
Learn more about new data presented at #ESCCongress from our open-label extension study of our treatment for severe hypertriglyceridemia (#sHTG): bit.ly/3SgSwwZ
Next week, we are sharing new data on the management of severe hypertriglyceridemia (#sHTG) at #ESCCongress. Read more: bit.ly/3U88RV7
We are honored that our medicine for familial chylomicronemia syndrome (FCS) has been nominated for the #PrixGalien USA award for Best Biotechnology Product. Read more: prn.to/3RJGv2R
Today we reported Q2 2026 financial results. Read more and tune in live to the webcast today at 8:30 AM ET to hear our second quarter highlights: bit.ly/4gXSFzb
$IONS
